Form 4: Syndax Pharmaceuticals CFO Sells Shares for Tax Obligations

Syndax Pharmaceuticals' Chief Financial Officer, Keith A. Goldan, reported the sale of 1,296 shares of common stock on July 16, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals Inc. (SNDX), reported a transaction on July 16, 2025.
• The transaction involved the sale of 1,296 shares of Syndax Pharmaceuticals common stock.
• The shares were sold at a price of $9.285 per share.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Goldan beneficially owns 92,450 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes, which is neutral in sentiment. It does not indicate a lack of confidence from management, nor does it represent a positive strategic move.

Positives

• The sale is non-discretionary, specifically for tax withholding, which is a routine event and not indicative of a lack of confidence in the company.

Negatives

• A reduction in direct insider ownership, even if for tax purposes, slightly decreases the alignment of management's personal holdings with shareholder interests.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the routine nature of insider transactions.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes, which is common across all industries when restricted stock units vest. It does not provide specific insights into broader pharmaceutical industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature of the sale mitigates concerns about management confidence.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

Keywords

Syndax Pharmaceuticals, SNDX, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Keith A. Goldan, CFO